Literature DB >> 30007895

Krebs von den Lungen-6 associated with chest high-resolution CT score in evaluation severity of patients with interstitial lung disease.

H Qin1, X P Xu2, J Zou1, X J Zhao1, H W Wu3, Q F Zha1, S Chen4, Y Kang5, H D Jiang6.   

Abstract

AIMS: The purpose of this prospective, single-center study was to measure the value of Krebs von den Lungen-6 (KL-6), a kind of transmembrane mucoprotein, in diagnosing interstitial lung disease (ILD) and in assessing the severity of ILD.
METHODS: We enrolled 184 patients and 30 healthy controls. Ninety-eight patients were diagnosed with ILD, 47 with pneumonia, 19 with non-small cell lung cancer without ILD (NSCLC/non-ILD) and 20 with other lung diseases. Serum KL-6 levels, CT scores of high-resolution computerised tomography (HRCT) and pulmonary function in ILD patients were assessed.
RESULTS: The mean value of serum KL-6 in patients with ILD, pneumonia, NSCLC/non-ILD, other lung diseases and healthy controls were 1000.67±882.73U/ml, 234.11±91.02U/ml, 269.95±149.23U/ml, 234.85±83.51U/ml and 189.03±55.50U/ml, respectively. Serum KL-6 levels of patients with ILD were significantly higher than that of other groups (P<0.000). The level of serum KL-6 in patients with pneumonia, NSCLC/non-ILD and other lung diseases was also statistically higher than healthy controls (P<0.05). When the cut-off value was 312U/ml, the sensitivity and specificity of KL-6 for the diagnosis of ILD was 84.7% and 85.3% respectively (AUC: 0.936, 95% CI: 0.906-0.965). The serum KL-6 levels in patients with ILD were significantly positively correlated with the CT scores (r=0.539, P=0.000) and negatively correlated with DLCO (r=-0.513, P=0.000).
CONCLUSION: Serum KL-6 might be useful in the diagnosis of ILD, especially in the hard-to-diagnose cases, with high sensitivity and specificity. Furthermore, KL-6 might be a valuable marker for evaluation of ILD severity.
Copyright © 2018 Sociedade Portuguesa de Pneumologia. Published by Elsevier España, S.L.U. All rights reserved.

Entities:  

Keywords:  Computed tomography; Interstitial lung disease; Krebs von den Lungen-6; Pneumonia; Pulmonary function test

Year:  2018        PMID: 30007895     DOI: 10.1016/j.pulmoe.2018.05.008

Source DB:  PubMed          Journal:  Pulmonology        ISSN: 2531-0429


  5 in total

1.  Serum Krebs von den Lungen-6 for Predicting the Severity of COVID-19 Lung Injury: A Systematic Review and Meta-Analysis.

Authors:  Andro Pramana Witarto; Bendix Samarta Witarto; Achmad Januar Er Putra; Shidi Laras Pramudito; Alfian Nur Rosyid
Journal:  Iran Biomed J       Date:  2021-11-01

2.  Blood KL-6 predicts prognosis in primary Sjögren's syndrome-associated interstitial lung disease.

Authors:  Yun Jae Kim; Jooae Choe; Su-Jin Moon; Jin Woo Song
Journal:  Sci Rep       Date:  2022-03-29       Impact factor: 4.379

3.  Establishment and validation of nomogram for predicting immuno checkpoint inhibitor related pneumonia.

Authors:  Xiaoqi Li; Fei Lv; Ying Wang; Zhenguang Du
Journal:  BMC Pulm Med       Date:  2022-09-01       Impact factor: 3.320

4.  Whole genome sequencing to identify predictive markers for the risk of drug-induced interstitial lung disease.

Authors:  Chihiro Udagawa; Hidehito Horinouchi; Kouya Shiraishi; Takashi Kohno; Takuji Okusaka; Hideki Ueno; Kenji Tamura; Yuichiro Ohe; Hitoshi Zembutsu
Journal:  PLoS One       Date:  2019-10-04       Impact factor: 3.240

5.  Synergistic combination of a topologically invariant imaging signature and a biomarker for the accurate prediction of symptomatic radiation pneumonitis before stereotactic ablative radiotherapy for lung cancer: A retrospective analysis.

Authors:  Kenta Ninomiya; Hidetaka Arimura; Tadamasa Yoshitake; Taka-Aki Hirose; Yoshiyuki Shioyama
Journal:  PLoS One       Date:  2022-01-31       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.